How many drug targets are there?
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation (the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, G-protein-coupled receptors (GPCRs) are influenced by trafficking progress and then internalized in the cell membrane and recycled or degraded.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
In the citing paper
“Covalent molecules may not be able to effectively target GPCRs during this turnover process [127].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [127]
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The Pfam Protein Families Database
Bateman, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,000
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Murzin, A. G., Brenner, S. E., Hubbard, T., & Chothia, C. (1995) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80134-2 · Cited by 7,012 · cited 1×
“Patterns in drug targets In order to identify the familial relationships between all drug targets, we analysed the presence of domains, using the SCO”
MethodDrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“drugs acted primarily through only 120 underlying molecular target”
BackgroundSelf-citationThe Pfam protein families database
Bateman, A. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh121 · Cited by 3,127
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967 · cited 1×
“Imatinib, originally developed as a highly selective inhibitor of c-AB”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“(and which target association led to its first approval for chronic myeloid leukaemia), has subsequently been discovered to be have significant activity against several other clinically relevant kinases, such as c-KI”
Background
Research works printed but not linked: 1
- Christensen, C. M. The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail (Harvard Business School Press, Cambridge, 1997).
Cited by
Items 301–400 of 1,024
Wu, Z., Graybill, T. L., Zeng, X., Platchek, M., Zhang, J., Bodmer, V. Q., Wisnoski, D. D., Deng, J., Coppo, F. T., Yao, G., et al. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00124 · Cited by 135
Triggered azobenzene-based prodrugs and drug delivery systems
Zhu, J., Guo, T., Wang, Z., & Zhao, Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.041 · Cited by 141
Drug target miRNAs: chances and challenges
Schmidt, M. F. (2014) · Trends in biotechnology · doi:10.1016/j.tibtech.2014.09.002 · Cited by 145
Emerging Functional Divergence of β-Arrestin Isoforms in GPCR Function
Srivastava, A., Gupta, B., Gupta, C., & Shukla, A. K. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.09.001 · Cited by 160
Knowles, H. M., Li, Y., & Perraud, A. (2012) · Immunologic Research · doi:10.1007/s12026-012-8373-8 · Cited by 137
“Given their localization at the surface of cells and the possibility to pharmacologically modulate their activity, ion channels are second only to GPCR regarding the number of therapeutically validated targets they provide [3, 4].”
BackgroundAssessment of helical interfaces in protein–protein interactions
Jochim, A. L., & Arora, P. S. (2009) · Molecular BioSystems · doi:10.1039/b903202a · Cited by 134
Adhesion G Protein-Coupled Receptors: Signaling, Pharmacology, and Mechanisms of Activation
Paavola, K. J., & Hall, R. A. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080309 · Cited by 151
“The diversity of ligands that GPCRs are able to detect and the multitude of downstream signaling pathways make GPCRs important drug targets, with approximately 30% of all current therapeutic agents acting directly on GPCRs (Overington et al., 2006).”
BackgroundSoto‐Cerrato, V., Manuel-Manresa, P., Hernando, E., Fariñas, S. C., Martínez‐Romero, A., Fernández‐Dueñas, V., Sahlholm, K., Knöpfel, T., García‐Valverde, M., Rodilla, A. M., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09970 · Cited by 138
Buchwald, P. (2010) · IUBMB Life · doi:10.1002/iub.383 · Cited by 133
“For example, achieving a Kd 5 20 nM, the average of existing small molecule drugs (35), with an LE 5 1 kJ/atom requires a structure with [45 nonhydrogen atoms, which is around the limit of ‘‘druggability’’ highlighting the importance for the need of structures that can show good protein binding.”
BackgroundTargeting intrinsically disordered proteins at the edge of chaos
Ruan, H., Sun, Q., Zhang, W., Liu, Y., & Lai, L. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.017 · Cited by 133
Targeting enzyme inhibitors in drug discovery
Copeland, R. A., Harpel, M. R., & Tummino, P. J. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.7.967 · Cited by 152
“The combination of high target validation and high target tractability (more recently dubbed target druggability [15-17] ) have led many in the pharmaceutical community to consider enzymes the most attractive targets to pursue for drug-seeking efforts.”
BackgroundCharacteristics of known drug space. Natural products, their derivatives and synthetic drugs
Bade, R., Chan, H., & Reynisson, J. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.018 · Cited by 134
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Drewry, D. H., & Macarrón, R. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.024 · Cited by 145
The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling
Bock, A., Merten, N., Schrage, R., Dallanoce, C., Bätz, J., Klöckner, J., Schmitz, J., Matera, C., Simon, K., Kebig, A., et al. (2012) · Nature Communications · doi:10.1038/ncomms2028 · Cited by 132
“(c) Receptor binding poses of dualsteric probes in the absence (1,2) and presence (3) of an orthosteric ligand.”
Wu, Z., Cheng, F., Li, J., Li, W., Liu, G., & Tang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw012 · Cited by 143
Pharmacology and Signaling of MAS-Related G Protein–Coupled Receptors
Solinski, H. J., Gudermann, T. W., & Breit, A. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008425 · Cited by 148
“(Overington et al., 2006).”
Efficient Characterization of Protein Cavities within Molecular Simulation Trajectories:trj_cavity
Paramo, T., East, A., Garzón, D., Ulmschneider, M. B., & Bond, P. J. (2014) · Journal of Chemical Theory and Computation · doi:10.1021/ct401098b · Cited by 134
Garton, M., Nim, S., Stone, T. A., Wang, K. E., Deber, C. M., & Kim, P. M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711837115 · Cited by 138
“Importantly, this target size limitation largely precludes membrane proteins, which comprise ∼60% of all therapeutic targets (23).”
BackgroundA physical wiring diagram for the human immune system
Shilts, J., Severin, Y., Galaway, F., Müller-Sienerth, N., Chong, Z.-S., Pritchard, S., Teichmann, S., Vento-Tormo, R., Snijder, B., & Wright, G. J. (2022) · Nature · doi:10.1038/s41586-022-05028-x · Cited by 125
Objective assessment of cancer genes for drug discovery
Patel, M. N., Halling‐Brown, M., Tym, J. E., Workman, P., & Al‐Lazikani, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3913 · Cited by 149
“2a) of the Census proteins to that of the targets of small-molecule pharmaceuticals approved by the US Food and Drug Administration (FDA), across all therapeutic areas as well as for oncology alone 29 .”
BackgroundInfluentialSelf-citationManteniotis, S., Lehmann, R., Flegel, C., Vogel, F. C. E., Hofreuter, A., Schreiner, B., Altmüller, J., Becker, C., Schöbel, N., Hatt, H. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079523 · Cited by 144
“The receptor family of GPCRs plays a major role in physiological and pathophysiological processes [22,23], and approximately 40-60% of all current drugs target receptors of this class [15,24].”
BackgroundHerbert, C., Schieborr, U., Saxena, K., Juraszek, J., Smet, F. D., Alcouffe, C., Bianciotto, M., Saladino, G., Sibrac, D., Kudlinzki, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.018 · Cited by 141
“Receptor tyrosine kinases (RTKs) constitute a major class of drug targets (Overington et al., 2006).”
BackgroundPandey, A. N., Shin, K., Patterson, R. E., Liu, X., & Rainey, J. K. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2015-0143 · Cited by 147
“The importance of membrane proteins is also highlighted by the facts that they represent ~26% of the human proteome (Fagerberg et al. 2010) and that >50% of currently marketed drugs target this class of proteins (Arinaminpathy et al. 2009; Overington et al. 2006; Yildirim et al. 2007).”
BackgroundWang, Q., Chen, R., Cheng, F., Wei, Q., Ji, Y., Yang, H., Zhong, X., Tao, R., Wen, Z., Sutcliffe, J. S., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0382-7 · Cited by 136
How functional foods play critical roles in human health
Pang, G., Xie, J., Chen, Q., & Zhi-he, H. (2012) · Food Science and Human Wellness · doi:10.1016/j.fshw.2012.10.001 · Cited by 152
Structure-based ligand discovery for the protein–protein interface of chemokine receptor CXCR4
Mysinger, M. M., Weiss, D. R., Ziarek, J. J., Gravel, S., Doak, A. K., Karpiak, J., Heveker, N., Shoichet, B. K., & Volkman, B. F. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120431109 · Cited by 132
“G receptors (GPCRs) play a central role in many normal physiological pathways and altered diseased states, and are the targets of approximately 30% of marketed drugs (1).”
BackgroundLi, L., Wang, Q., Zhang, Y., Niu, Y., Yao, X., & Liu, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120330 · Cited by 152
“Food and Drug Administration (FDA) approved drugs are nuclear receptors [28].”
BackgroundSphingosine 1-Phosphate Receptor Modulators and Drug Discovery
Park, S.-J., & Im, D.-S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.160 · Cited by 130
“Many ligands, including hormones, autacoids, neurotransmitters, and very small molecules to large proteins can bind and activate GPCRs, and their activations lead to a multitude of physiological processes (Howard et al., 2001; Overington et al., 2006; Im, 2013).”
BackgroundGPCRDB: information system for G protein-coupled receptors
Vroling, B., Sanders, M., Baakman, C., Borrmann, A., Verhoeven, S., Klomp, J., Oliveira, L., de Vlieg, J., & Vriend, G. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1009 · Cited by 129
“GPCRs are a major target for the pharmaceutical industry as is reflected by the fact that more than a quarter of all FDA approved drugs act on a GPCR (1).”
BackgroundEngineering antibodies for clinical applications
Jain, M., Kamal, N., & Batra, S. K. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.05.001 · Cited by 151
G protein-coupled receptors as promising cancer targets
Liu, Y., An, S., Ward, R. J., Yang, Y., Guo, X., Li, W., & Xu, T. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.031 · Cited by 144
2-Aminothiophene scaffolds: Diverse biological and pharmacological attributes in medicinal chemistry
Bozorov, K. A., Nie, L., Zhao, J., & Aisa, H. A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.039 · Cited by 128
Mechanistic insights into GPCR–G protein interactions
Mahoney, J. P., & Sunahara, R. K. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.11.005 · Cited by 151
“Due to the heavy involvement of GPCRs in regulating physiological processes, these receptors are of great therapeutic importance and therefore are targeted by ~30% of currently-marketed pharmaceutical drugs [2].”
BackgroundIon channels as therapeutic antibody targets
Hutchings, C. J., Colussi, P. A., & Clark, T. G. (2018) · mAbs · doi:10.1080/19420862.2018.1548232 · Cited by 146
Graph convolution for predicting associations between miRNA and drug resistance
Huang, Y., Hu, P., Chan, K. C. C., & You, Z. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz621 · Cited by 142
Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration
Rives, M., Vol, C., Fukazawa, Y., Tinel, N., Trinquet, E., Ayoub, M. A., Shigemoto, R., Pin, J., & Prézeau, L. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.177 · Cited by 133
“…Shigemoto4, Jean-Philippe Pin1,2,3 and Laurent Prézeau1,2,3,* 1Department of Molecular Pharmacology, CNRS, UMR 5203, Institut de Génomique fonctionnelle, Montpellier, France, 2INSERM U661, Montpellier, France, 3Université Montpellier, Montpellier, France, 4Division of Cerebral Structure,…”
BackgroundAtomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database
Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009598 · Cited by 126
“The number of currently available drug targets is very limited [18].”
BackgroundNative Mass Spectrometry of Membrane Proteins
Keener, J. E., Zhang, G., & Marty, M. T. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c04342 · Cited by 126
Structures of G protein-coupled receptors reveal new opportunities for drug discovery
Cooke, R. M., Brown, A., Marshall, F. H., & Mason, J. S. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.003 · Cited by 133
Bodine, P. V. N., Stauffer, B., Ponce‐de‐Leon, H., Bhat, R. A., Mangine, A., Seestaller‐Wehr, L., Moran, R. A., Billiard, J., Fukayama, S., Komm, B. S., et al. (2009) · Bone · doi:10.1016/j.bone.2009.02.013 · Cited by 144
“Even though sFRP-1 is a secreted protein that would not typically be considered as a drug target for orally active compounds [47], we chose to develop small molecular weight inhibitors of this Wnt pathway antagonist, as these kinds of drugs are the most cost effective therapies for diseases like osteoporosis.”
BackgroundNeoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
Lee, J. A., & Berg, E. L. (2013) · SLAS Discovery · doi:10.1177/1087057113506118 · Cited by 126
Tang, J., Cores, J., Huang, K., Cui, X., Luo, L., Zhang, J.-Y., Li, T., Li, Q., & Cheng, K. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0196 · Cited by 134
Vuorinen, A., & Schuster, D. (2014) · Methods · doi:10.1016/j.ymeth.2014.10.013 · Cited by 133
TargetMine, an Integrated Data Warehouse for Candidate Gene Prioritisation and Target Discovery
Chen, Y.-A., Tripathi, L. P., & Mizuguchi, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017844 · Cited by 126
“TFs are of immense significance in biomedical investigations and some TFs such as nuclear receptors are important drug targets [36,37].”
BackgroundComputational Peptidology: A New and Promising Approach to Therapeutic Peptide Design
Zhou, P., Wang, C., Ren, Y., Yang, C., & Tian, F. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320150005 · Cited by 128
Mei, F., Mayoral, S. R., Nobuta, H., Wang, F., Desponts, C., Lorrain, D. S., Xiao, L., Green, A. J., Rowitch, D., Whistler, J., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1493-16.2016 · Cited by 122
“GPCRs are therapeutically targeted by 40% of all modern medicinal drugs (Overington et al., 2006); therefore, GPCRs are likely targetable receptors for the development of small molecule therapeutics for remyelination.”
BackgroundMarciano, D. P., Chang, M. R., Corzo, C. A., Goswami, D., Lam, V. Q., Pascal, B. D., & Griffin, P. R. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2013.12.009 · Cited by 140
“NRs are the molecular target of approximately 10%–15% of drugs currently approved by the FDA, highlighting their tractability for therapeutic intervention (Overington et al., 2006).”
BackgroundMechanisms and Synthetic Modulators of AHL-Dependent Gene Regulation
Stevens, A. M., Queneau, Y., Soulère, L., von Bodman, S. B., & Doutheau, A. (2010) · Chemical Reviews · doi:10.1021/cr100064s · Cited by 125
Probing disease-related proteins with fluorogenic composite materials
He, X., Zang, Y., James, T. D., Li, J. X., & Chen, G. (2014) · Chemical Society Reviews · doi:10.1039/c4cs00252k · Cited by 123
Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors
Sridharan, R., Zuber, J., Connelly, S. M., Mathew, E., & Dumont, M. E. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.09.005 · Cited by 148
Lerner, M. B., Matsunaga, F., Han, G., Hong, S. J., Jin, X., Crook, A. L., Perez‐Aguilar, J. M., Park, Y. W., Saven, J. G., Liu, R., et al. (2014) · Nano Letters · doi:10.1021/nl5006349 · Cited by 134
Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery
Mercola, M., Colas, A., & Willems, E. (2013) · Circulation Research · doi:10.1161/circresaha.111.250266 · Cited by 122
“It is thought that there are >1 000 000 total human proteins, including splice variants, posttranslational modifications, and somatic mutants,(64) greatly overshadowing the calculated 3000 to 10 0000 so-called druggable proteins and the ≈500 proteins targeted by our current pharmacopeia, although few small molecules c…”
BackgroundPrediction of Synergism from Chemical-Genetic Interactions by Machine Learning
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.003 · Cited by 121
“…despite investments in genome-based approaches for target identification, validation, and screening, the current repertoire of approved drugs targets stands at only 500 proteins, with at most only a further 500 targets under active exploration (Overington et al., 2006; Rask-Andersen et al., 2014).”
Parisi, D., Adasme, M. F., Sveshnikova, A. N., Bolz, S. N., Moreau, Y., & Schroeder, M. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.004 · Cited by 136
“Examples of such databases are the Therapeutic Targets Database [55], Drugbank[56], SuperTarget [57], and the IUPHAR/BPS Guide [58].”
BackgroundSheridan, R. P., Maiorov, V. N., Holloway, M. K., Cornell, W. D., & Gao, Y. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100312t · Cited by 126
Engineering and Identifying Supercharged Proteins for Macromolecule Delivery into Mammalian Cells
Thompson, D. B., Cronican, J. J., & Liu, D. R. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-396962-0.00012-4 · Cited by 124
“Indeed, 180 protein drugs are currently prescribed including insulin, erythropoietin, interferons, and a variety of antibodies (Overington et al., 2006).”
Therapeutic target database update 2014: a resource for targeted therapeutics
Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 121
Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins
Boonstra, M. C., de Geus, S. W. L., Prevoo, H. A. J. M., Hawinkels, L. J. A. C., de Velde, C. J. H. V., Kuppen, P. J. K., Vahrmeijer, A. L., & Sier, C. F. M. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s38542 · Cited by 135
Adhesion G Protein–Coupled Receptors as Drug Targets
Purcell, R. H., & Hall, R. A. (2017) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052933 · Cited by 129
Why Some Targets Benefit from beyond Rule of Five Drugs
Egbert, M., Whitty, A., Keserű, G. M., & Vajda, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01732 · Cited by 118
Intellectual property protection
Storz, U. (2011) · mAbs · doi:10.4161/mabs.3.3.15530 · Cited by 118
Michino, M., Beuming, T., Donthamsetti, P., Newman, A. H., Javitch, J. A., & Shi, L. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009944 · Cited by 118
“ical targets for many diseases (Overington et al., 2006).”
Chemical Genetics–Based Target Identification in Drug Discovery
Cong, F., Cheung, A. K., & Huang, S.-M. A. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134639 · Cited by 145
A Selective Luminescent Probe for the Direct Time-Gated Detection of Adenosine Triphosphate
Weitz, E. A., Chang, J. Y., Rosenfield, A. H., & Pierre, V. C. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304373u · Cited by 118
Ligand binding at the protein–lipid interface: strategic considerations for drug design
Payandeh, J., & Volgraf, M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00240-2 · Cited by 128
Systematic identification of proteins that elicit drug side effects
Kuhn, M., Al Banchaabouchi, M., Campillos, M., Jensen, L. J., Gross, C., Gavin, A., & Bork, P. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.10 · Cited by 120
Valant, C., May, L. T., Aurelio, L., Chuo, C. H., White, P. J., Baltos, J., Sexton, P. M., Scammells, P. J., & Christopoulos, A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320962111 · Cited by 125
“G protein-coupled receptors (GPCRs) are the largest family of cell surface proteins and tractable drug targets (1, 2).”
BackgroundInfluentialiGPCR-Drug: A Web Server for Predicting Interaction between GPCRs and Drugs in Cellular Networking
Xiao, X., Min, J., Wang, P., & Chou, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072234 · Cited by 121
“Over half of all prescription drugs currently on the market are actually acting by targeting GPCRs directly or indirectly [5,6].”
BackgroundDrug Target Protein-Protein Interaction Networks: A Systematic Perspective
Feng, Y., Wang, Q., & Wang, T. (2017) · BioMed Research International · doi:10.1155/2017/1289259 · Cited by 118
García‐Nafría, J., & Tate, C. G. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023545 · Cited by 132
Heifetz, A., Chudyk, E. I., Gleave, L., Aldeghi, M., Cherezov, V., Fedorov, D. G., Biggin, P. C., & Bodkin, M. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00644 · Cited by 116
Cortés-Ciriano, I., Ain, Q. U., Subramanian, V., Lenselink, E. B., Méndez-Lucio, O., IJzerman, A. P., Wohlfahrt, G., Prusis, P., Malliavin, T. E., van Westen, G. J. P., et al. (2015) · MedChemComm · doi:10.1039/c4md00216d · Cited by 116
Abad‐Zapatero, C., Perišić, O., Wass, J. A. H., Bento, A. P., Overington, J. P., Al‐Lazikani, B., & Johnson, M. E. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.08.004 · Cited by 116
Self-citationLuminescent Lanthanide Cryptates: from the Bench to the Bedside
Zwier, J. M., Bazin, H., Lamarque, L., & Mathis, G. (2014) · Inorganic Chemistry · doi:10.1021/ic402234k · Cited by 123
Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases
Tao, Y.-X., & Conn, P. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00029.2016 · Cited by 115
“They are the leading therapeutic targets in the pharmaceutical market, accounting for 30% of sales, including some of the most commonly prescribed medications (270).”
BackgroundInhibition of transcription factors with small organic molecules
Berg, T. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.07.023 · Cited by 139
Prediction of potential drug targets based on simple sequence properties
Li, Q., & Lai, L. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-353 · Cited by 115
“Datasets 186 targets of approved oral small-molecular drugs were taken as the positive dataset in this study, which were recently revised by Overington et al[2].”
InfluentialWhat makes a good drug target?
Gashaw, I., Ellinghaus, P., Sommer, A., & Asadullah, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.008 · Cited by 122
Labeling and Single-Molecule Methods To Monitor G Protein-Coupled Receptor Dynamics
Tian, H., Fürstenberg, A., & Huber, T. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00084 · Cited by 114
Cheng, F., Zhou, Y., Li, J., Li, W., Liu, G., & Tang, Y. (2012) · Molecular BioSystems · doi:10.1039/c2mb25110h · Cited by 127
Villoutreix, B. O., Kuenemann, M. A., Poyet, J., Bruzzoni‐Giovanelli, H., Labbé, C., Lagorce, D., Sperandio, O., & Miteva, M. A. (2014) · Molecular Informatics · doi:10.1002/minf.201400040 · Cited by 116
Awale, M., & Reymond, J. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0199-x · Cited by 130
“The vast majority of small molecule drugs interact with multiple targets, a general phenomenon known as polyp-harmacology and a key parameter to be addressed in the course of drug development [1–3].”
BackgroundTargeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 125
“It can be said that currently there is an active search for new targets that would provide effective antitumor treatment [225,226].”
BackgroundControl of bone formation by the serpentine receptor Frizzled-9
Albers, J., Schulze, J., Beil, F. T., Gebauer, M., Baranowsky, A., Keller, J., Marshall, R. P., Wintges, K., Friedrich, F. W., Priemel, M., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201008012 · Cited by 114
“…is of tremendous importance to fill this apparent gap in our understanding of Wnt signaling in bone cells because Fzd proteins belong to the family of serpentine receptors, which represent the major class of target proteins for currently available drugs (Wise et al., 2002; Overington et al., 2006).”
Extrasensory perception: Odorant and taste receptors beyond the nose and mouth
Foster, S. R., Roura, E., & Thomas, W. G. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.004 · Cited by 130
“…of GPCRs, G proteins and their regulatory partners are linked to dysfunction and disease (Drews, 2000; Hopkins & Groom, 2002; Wettschureck & Offermanns, 2005; Overington et al., 2006), and the importance of these receptors is reflected in the fact that 40% of drugs on the market target GPCRs.”
BackgroundBedbrook, C. N., Yang, K. K., Rice, A. J., Gradinaru, V., & Arnold, F. H. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005786 · Cited by 113
“As crucial components of regulatory and transport pathways, integral membrane proteins (MPs) are important pharmaceutical and engineering targets [1].”
BackgroundLin, J., Chen, H., Li, S., Liu, Y., Li, X., & Yu, B. (2019) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2019.07.005 · Cited by 116
The rat sperm proteome characterized via IPG strip prefractionation and LC‐MS/MS identification
Baker, M. A., Hetherington, L., Reeves, G., Müller, J., & Aitken, R. J. (2008) · PROTEOMICS · doi:10.1002/pmic.200700876 · Cited by 113
Ivetac, A., & Andrew McCammon, J. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01012.x · Cited by 112
“Testament to this, GPCRs are associated with approximately 30% of current drugs (4) and are linked to such diseases as cancer (5) and those of the cardiovascular and central nervous systems (6,7).”
BackgroundFunctional crosstalk between GPCRs: with or without oligomerization
Prézeau, L., Rives, M., Comps‐Agrar, L., Maurel, D., Kniazeff, J., & Pin, J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.10.009 · Cited by 119
“Indeed, GPCRs, formed by seven helix-containing proteins (7TM proteins) coded by the largest mammalian gene family, are already the targets of about 30% of the drugs on the market [5].”
BackgroundGPCR signaling inhibits mTORC1 via PKA phosphorylation of Raptor
Jewell, J. L., Fu, V. X., Hong, A. W., Yu, F., Meng, D., Melick, C. H., Wang, H., Lam, W.-L. M., Yuan, H.-X., Taylor, S. S., et al. (2019) · eLife · doi:10.7554/elife.43038 · Cited by 122
gene2drug: a computational tool for pathway-based rational drug repositioning
Napolitano, F., Carrella, D., Mandriani, B., Pisonero-Vaquero, S., Sirci, F., Medina, D. L., Brunetti-Pierri, N., & di Bernardo, D. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx800 · Cited by 108
Versatile Phospholipid Assemblies for Functional Synthetic Cells and Artificial Tissues
Wang, X., Du, H., Wang, Z., Mu, W., & Han, X. (2020) · Advanced Materials · doi:10.1002/adma.202002635 · Cited by 113
Soluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Zeisel, M., Lupberger, J., Fofana, I., & Baumert, T. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.09.022 · Cited by 114
“Moreover, the majority of current drugs widely used for cardiovascular, neurological or endocrine diseases as well as cancer, targets host proteins [115-117].”
BackgroundRecent advances in the search for D3- and D4-selective drugs: probes, models and candidates
Löber, S., Hübner, H., Tschammer, N., & Gmeiner, P. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.003 · Cited by 114
GPR68, a proton‐sensing GPCR, mediates interaction of cancer‐associated fibroblasts and cancer cells
Wiley, S. Z., Sriram, K., Liang, W., Chang, S. E., French, R., McCann, T., Sicklick, J., Nishihara, H., Lowy, A. M., & Insel, P. A. (2018) · The FASEB Journal · doi:10.1096/fj.201700834r · Cited by 110
“Food and Drug Administration–approved drugs (15, 16).”
Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy
Zhao, R., Fu, J., Zhu, L., Chen, Y., & Liu, B. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01230-6 · Cited by 113
Caffrey, C. R., Rohwer, A., Oellien, F., Marhöfer, R. J., Braschi, B., Oliveira, G., McKerrow, J. H., & Selzer, P. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004413 · Cited by 112
“Our strategy, therefore, to identify homologous rather than pathogenspecific potential targets is intended to reduce costs by leveraging the biochemical, chemical and structural data and tools already available for therapeutic targets of proven value in other clinical contexts, i.e., ‘piggy-back’ drug discovery [43,44…”
Background
Metadata
- Authors
- Overington, J. P., Al-Lazikani, B., & Hopkins, A. L.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Overington, John P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12
- Volume
- 5
- Issue
- 12
- Pages
- 993-996
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1968682237
- Cited by
- 3,505
- References
- 29
- Citations by year
- 2026: 82 · 2025: 126 · 2024: 117 · 2023: 127 · 2022: 173 · 2021: 168 · 2020: 190 · 2019: 190 · 2018: 198 · 2017: 215 · 2016: 276 · 2015: 268 · 2014: 245 · 2013: 280 · 2012: 247
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- therapeutic target, molecular targets, protein kinases, polypharmacology, approved drugs
- MeSH terms
- Humans, Technology, Pharmaceutical, Drug Design, Drugs, Investigational, Genome, Human, Drug Delivery Systems, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.